{"entity":{"id":"nct06593522","kind":"trial","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","aka":[],"tldr":"A phase 2 trial of Anvumetostat in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) is a phase 2 interventional study registered as NCT06593522 by Amgen, with 61 participants enrolled, started 2024-12-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: anvumetostat.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06593522","url":"https://clinicaltrials.gov/study/NCT06593522"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["anvumetostat"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06593522","phase":"2","setting":"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Amgen","enrolled":61,"outcomes":[]},"route":"/trials/nct06593522/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","route":"/drugs/anvumetostat/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}